Supramolecular NanoChemistry and Materials Group

Group Leader: Daniel Maspoch

Daniel Maspoch

ICREA Prof Daniel Maspoch

Group Leader

Dr. Daniel Maspoch is a chemist who has always maintained a rewarding balance between fundamental and applied research, making pioneering contributions in both in the field of porous metal-organic frameworks (MOFs) and delivery systems.

His scientific career began with a degree in chemistry at the Universitat de Girona, followed by a PhD in materials science from the Universitat Autònoma de Barcelona and the Institut de Ciència de Materials de Barcelona. He then spent two years at Northwestern University (USA) as a postdoctoral fellow in the group led by Prof. Chad A. Mirkin. He has been an ICREA research professor and group leader at the ICN2 since September 2011. In 2014 Prof. Maspoch was awarded a prestigious ERC Consolidator Grant for the InanoMOF project to develop frontier methodologies for the synthesis of nanocomposites made from MOFs. In 2015 he received the Marcial Moreno Mañas Lectureship award. He has authored over 115 papers and five book chapters.

Several technologies and materials developed under his leadership are currently being used by companies with products on the market. In total Prof. Maspoch has signed more than 15 research contracts with private companies and filed 10 patents, of which four have been licensed. He has also signed four technology transfer contracts that have given rise to different product families such as LuctaCaps® and Fungipol@CP. Most recently he has co-founded the spin-off Ahead Therapeutics S.L.

He moved back to the then ICN thanks to a Ramón y Cajal contract, where he founded the ICN2 Supramolecular Nanochemistry and Materials Group. He has been an ICREA Research Professor and group leader at the ICN2 since September 2011. In 2014 he was awarded an ERC Consolidator Grant.

Prof. Maspoch has authored 97 scientific publications and five book chapters. He has also filed eight patents and established 14 contracts with private companies, including two patent licence agreement and three successful transfers of in-house technology for immediate application in consumer products.